Abecma Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to breakthrough CAR T clinical outcomes, rising multiple myeloma incidence, limited alternatives for refractory patients, regulatory approvals for cell therapies, oncology center adoption.

The growth in the forecast period can be attributed to expansion into earlier treatment lines, improvements in manufacturing efficiency, increasing oncology investment, growing patient eligibility, development of next generation CAR T therapies. Major trends in the forecast period include rising adoption of CAR T cell therapies, expansion of advanced cell based oncology, growth of personalized cancer treatments, increasing use in refractory multiple myeloma, advancements in autologous cell processing.

The increasing prevalence of multiple myeloma is expected to drive the growth of the Abecma market in the coming years. Multiple myeloma is a form of blood cancer that affects plasma cells, a type of white blood cell located in the bone marrow. The rising incidence of multiple myeloma is attributed to factors such as an aging population, advances in diagnostic technologies, and greater awareness of the disease. Abecma, a CAR T-cell therapy, plays a significant role in treating multiple myeloma by using genetically engineered immune cells to specifically identify and eliminate cancerous plasma cells, providing a novel treatment option for patients with relapsed or refractory disease. For example, in January 2024, according to the American Cancer Society, a US-based non-profit organization focused on cancer elimination, the number of projected myeloma cases in 2024 was 35,780, up from 34,470 cases in 2022. As a result, the growing prevalence of multiple myeloma is fueling demand for Abecma, thereby driving market growth.

Companies operating in the Abecma market are increasingly concentrating on the development of advanced therapies such as chimeric antigen receptor T-cell (CAR T) therapy to improve patient outcomes, more precisely target specific cancer types, and expand treatment options for individuals with relapsed or refractory multiple myeloma. CAR T-cell therapy is a cutting-edge immunotherapy approach primarily used in the treatment of certain cancers, including leukemia and lymphoma, and involves modifying a patient’s own T cells to enhance their ability to recognize and destroy cancer cells. For instance, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received approval from the European Commission for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy intended for adult patients with relapsed and refractory multiple myeloma. This approval applies to patients who have previously received at least two lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody, and whose disease progressed after their most recent treatment.

In January 2024, 2Seventy Bio Inc., a US-based biotechnology company, entered into a partnership with Bristol Myers Squibb. Through this collaboration, 2Seventy Bio aims to support the continued growth of Abecma by expanding patient access and increasing awareness among healthcare professionals regarding its clinical benefits. The partnership also supports preparations for potential regulatory approvals that could broaden Abecma’s treatment indications. Bristol Myers Squibb is a US-based pharmaceutical company actively involved in the development and commercialization of Abecma.

Major companies operating in the abecma market are Bristol-Myers Squibb.

North America was the largest region in the abecma market in 2025. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the abecma market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the abecma market by increasing costs related to imported cell processing equipment, biologic reagents, and cold chain logistics. These impacts are most visible in hospital based CAR T treatment centers across North America, Europe, and Asia Pacific. High treatment costs are further affected by import duties on specialized components. However, tariffs are also encouraging localized cell therapy manufacturing and strengthening regional advanced therapy infrastructure.

The abecma market research report is one of a series of new reports that provides abecma market statistics, including abecma industry global market size, regional shares, competitors with a abecma market share, detailed abecma market segments, market trends and opportunities, and any further data you may need to thrive in the abecma industry. This abecma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma by targeting and destroying malignant plasma cells. This therapy works by reprogramming a patient’s own immune cells, specifically T cells, to recognize and eliminate cancer cells.

The primary indications for Abecma include multiple myeloma, B-cell lymphoma (BCL), and acute lymphoblastic leukemia (ALL). Multiple myeloma is a form of blood cancer that develops in plasma cells, a type of white blood cell located in the bone marrow. These therapies are used by end users such as adults and geriatric patients and are distributed through channels including hospitals and clinics, retail and specialty pharmacies, and online pharmacies.

The abecma market consists of sales of CAR T-cell therapies, personalized treatments, and immuno-oncology solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.